Droperidol

Droperidol is a dopamine D₂ receptor antagonist and belongs to the butyrophenone class of derivatives. Droperidol primarily blocks central dopamine D₂ receptors, especially those in the chemoreceptor trigger zone (CTZ) of the medulla. By preventing dopamine-mediated activation of the CTZ, droperidol reduces initiation of nausea and vomiting reflexes. Droperidol also blocks D₂ receptors in the limbic system and mesolimbic pathway, suppressing dopaminergic signaling and producing central effects such as sedation and anti-agitation, while also potentially affecting pathways involved in psychiatric symptoms.